Suggested remit - To evaluate the benefits and costs of OTL-101 within its marketing authorisation for treating adenosine deaminase deficiency–severe combined immunodeficiency caused by for national commissioning by NHS England.
 
Status Proposed
Process HST
ID number 1152

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
27 July 2018 - 24 August 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
22 August 2018 On receiving timing information from the company that will market the technology, NICE has agreed that scoping the topic at this time would not be appropriate. Consequently the consultation on the draft scope will not continue at this time. The consultation will then be rescheduled to take place in line with such timings. We apologise for any inconvenience this may cause.

For further information on how we develop guidance, please see our page about NICE highly specialised technologies guidance